On November 15, 2019 Bruker Corporation (Nasdaq: BRKR) reported it will present at the following conferences (Press release, Bruker, NOV 15, 2019, View Source [SID1234551386]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2019 Healthcare Conference, New York, NY
Tuesday, November 19, 2019, at 1:15 p.m. Eastern Time
Gerald Herman, Chief Financial Officer

Jefferies 2019 London Healthcare Conference, London, UK
Thursday, November 21, 2019, at 8:00 a.m. GMT
Gerald Herman, Chief Financial Officer

A live audio webcast of the Stifel 2019 Healthcare Conference presentation will be available in the Investor Relations section of the Company’s website at View Source A replay will be posted on the Bruker Investor Relations website after the event and will be available for 30 days following the presentation.

On November 15, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, reported that it will present data from an ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions" (ClinicalTrials.gov Identifier: NCT03947385) (Press release, Ideaya Biosciences, NOV 15, 2019, View Source [SID1234551385]). This clinical trial is evaluating the tolerability and preliminary clinical activity of IDE196 for the treatment of MUM and other solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations activating the PKC signaling pathway.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An update on the Phase 1 Dose-Escalation portion of the ongoing Phase 1/2 clinical trial will be provided, including:

Dosing schema for dose escalation cohorts
Patient enrollment by dose cohort
Patient baseline characteristics
Summary of adverse events
Duration of treatment through data cut-off (October 28, 2019)
Data will be presented at the 16th International Congress for the Society for Melanoma Research (SMR Congress) at the Grand America Hotel in Salt Lake City, Utah, November 20-23, 2019.

Dr. Matteo Carlino, Medical Oncologist, Westmead Hospital and University of Australia, Westmead, Australia, will provide a poster presentation at the SMR Congress on November 20, 2019, entitled: "A phase 1/2 study of IDE196 in patients with metastatic uveal melanoma or solid tumors harboring GNAQ/11 mutations or PRKC fusions."

Dr. Meredith McKean, MD, MPH, Investigator, Melanoma Research Program at Sarah Cannon Research Institute, Nashville, TN, will provide an oral presentation, at a related meeting hosted by the Melanoma Research Foundation’s CURE Ocular Melanoma (OM) initiative in conjunction with the SMR Congress, on November 20, 2019.

On November 15, 2019 Nordic Nanovector ASA (OSE: NANO) reported that members of its senior management team will participate and present at the following upcoming investor conferences during November and December (Press release, Nordic Nanovector, NOV 15, 2019, View Source [SID1234551384]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Healthcare Conference in London on 21 November
Life Science Investor Conference in Copenhagen on 27 November
Nordic-American Life Science Conference 2019 in New York on 5 December
DNB’s 10th annual Nordic Healthcare Conference in Oslo on 12 December
The company presentation to be given at these events will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentations on the first day of each conference.

On November 15, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, reported that management will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19th, 2019 at 8:35 am EST in New York, NY (Press release, X4 Pharmaceuticals, NOV 15, 2019, View Source [SID1234551383]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 15, 2019 Aptorum Group Limited (Nasdaq: APM) ("the Company") a biopharmaceutical company focused on the development of novel therapeutics to address certain global unmet medical needs, reported the results of its 2019 Annual General Meeting, which was held on November 14, 2019, in Hong Kong (Press release, Aptorum, NOV 15, 2019, View Source [SID1234551382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the Annual General Meeting, shareholders

re-elected all of the Company’s current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Dr. Justin Wu, Mr. Charles Bathurst, Dr. Mirko Scherer and Professor Douglas Arner as directors of the Company until the Company’s 2020 annual general meeting or until their respective successors are duly appointed and qualified; and
approved, ratified and confirmed the re-appointment of Marcum Bernsteun & Pinchuk LLP as the Company’s independent auditors for the year ending December 31, 2019 and authorized the Board of Directors to fix the remuneration of the auditors.